Pfizer mulls mountaineering US COVID vaccine value ~4 occasions after authorities program ends

Pfizer (NYSE:PFE) anticipates to boost the worth of its COVID vaccine to about 4 occasions the present value, to ~$110 to $130 per dose after the U.S. authorities’s present buy plan ends, Reuters reported citing a Pfizer govt Angela Lukin.

Lukin — who serves as World Main Care & U.S. President at Pfizer, as per her Linkedin web page — mentioned she expects the COVID shot could be made obtainable without charge to individuals who have personal insurance coverage or authorities paid insurance coverage, the report added.

The COVID vaccine is presently given free of charge to all by the federal government. The U.S. authorities pays ~$30 per dose to Pfizer and BioNTech for the vaccine, bought as Comirnaty.

The report added that Wall Road was anticipating value hikes due to weaker demand for COVID vaccines.

Earlier this week it was reported that that even the U.S. rollout of up to date COVID vaccines focusing on the Omicron subvariant have been off to a sluggish begin.

In 2023, the U.S. market is anticipated to maneuver in the direction of personal insurance coverage after the U.S. public well being emergency ends, the Reuters report added.

The World Well being Group (WHO) nevertheless, has reiterated that COVID-19 stays a world well being emergency.